BFM
CRDF icon

Boothbay Fund Management’s Cardiff Oncology CRDF Stock Holding History

Boothbay Fund Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-449
Closed -$416K – 1894
2021
Q1 		$416K Hold
449
– – 0.02% 1032
2020
Q4 		$808K Buy
+449
New +$7.89K 0.03% 575

Other funds holding CRDF

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Boothbay Fund Management's CRDF Position: Q1 2025 in Review

Boothbay Fund Management sold out of Cardiff Oncology (CRDF) in Q1 2025, closing a stake of 129,960 shares — an estimated $564K sold.

Boothbay Fund Management first reported a position in CRDF in Q4 2024 and held it in 1 quarter. The position peaked at $564K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2025.

  • Boothbay Fund Management reported no remaining Cardiff Oncology position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 129,960 Cardiff Oncology shares in Q1 2025, an estimated $564K.
  • Boothbay Fund Management first reported a position in Cardiff Oncology in Q4 2024 and held it in 1 quarter.
  • Boothbay Fund Management's Cardiff Oncology position peaked at $564K in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.